References
- Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic. Mol Ther [Internet] 2011 [cited 2013 Jun 26]; 19:432-8. Available from: http://www.nature.com/doifinder/10.1038/mt.2011.1; PMID:21358705; http://dx.doi.org/10.1038/mt.2011.1
- Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: “Are we nearly there yet?” Hum Gene Ther [Internet] 2009 [cited 2013 Jun 25]; 20:1229-39. Available from: http://www.liebertonline.com/doi/abs/10.1089/hum.2009.142; PMID:19702437; http://dx.doi.org/10.1089/hum.2009.142
- Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev [Internet] 2014; 257:107-26. Available from: http://doi.wiley.com/10.1111/imr.12131; PMID:24329793; http://dx.doi.org/10.1111/imr.12131
- Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev [Internet] 2014; 257:127-44. Available from: http://doi.wiley.com/10.1111/imr.12139; PMID:24329794; http://dx.doi.org/10.1111/imr.12139
- Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, et al. Induction therapy for adults with acute lymphoblastic leukemia : results of more than 1500 patients from the international ALL trial : MRC UKALL XII / ECOG E2993. Blood [Internet] 2005; 106:3760-7. Available from: http://www.bloodjournal.org/content/106/12/3760?sso-checked = true; PMID:16105981; http://dx.doi.org/10.1182/blood-2005-04-1623
- Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, et al. Salvage regimens with autologous transplantation for relapsed large B-Cell Lymphoma in the Rituximab Era. J Clin Oncol [Internet] 2010 [cited 2015 Jul 15]; 28:4184-90. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2010.28.1618; PMID:20660832; http://dx.doi.org/10.1200/JCO.2010.28.1618
- Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol [Internet] 2013 [cited 2013 Jun 4]; 10:267-76. Available from: http://www.nature.com/doifinder/10.1038/nrclinonc.2013.46; PMID:23546520; http://dx.doi.org/10.1038/nrclinonc.2013.46
- Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med [Internet] 2011 [cited 2013 Jun 25]; 365:725-33. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1103849; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
- Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in Leukemia. N Engl J Med [Internet] 2014; 371:1507-17. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1407222; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
- Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells : CARs take the front seat for hematologic malignancies. Blood [Internet] 2015; 123:2625-36. Available from: http://www.bloodjournal.org/content/123/17/2625?sso-checked=true; http://dx.doi.org/10.1182/blood-2013-11-492231
- Corrigan-Curay J, Kiem H-P, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, et al. T-Cell immunotherapy: looking forward. Mol Ther [Internet] 2014; 22:1564-74. Available from: http://www.nature.com/doifinder/10.1038/mt.2014.148; PMID:25186558; http://dx.doi.org/10.1038/mt.2014.148
- Davila ML, Bouhassira DCG, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol [Internet] 2014; 99:361-71. Available from: http://link.springer.com/10.1007/s12185-013-1479-5; PMID:24311149; http://dx.doi.org/10.1007/s12185-013-1479-5
- Tran AC, Zhang D, Byrn R, Roberts MR. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol [Internet] 1995 [cited 2013 Jun 18]; 155:1000-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7608531; PMID:7608531
- Hege KM, Cooke KS, Finer MH, Zsebo KM, Roberts MR. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. J Exp Med [Internet] 1996 [cited 2013 Jun 18]; 184:2261-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8976181; PMID:8976181; http://dx.doi.org/10.1084/jem.184.6.2261
- Schirrmann T, Pecher G. Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res [Internet] 2005 [cited 2015 Jul 15]; 29:301-6. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0145212604002474; PMID:15661266; http://dx.doi.org/10.1016/j.leukres.2004.07.005
- Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther [Internet] 2010 [cited 2010 Jul 19]; 17:147-54. Available from: http://www.nature.com/doifinder/10.1038/cgt.2009.61; PMID:19745843; http://dx.doi.org/10.1038/cgt.2009.61
- Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol [Internet] 2015; 6:1-7. Available from: http://journal.frontiersin.org/Article/10.3389/fphar.2015.00021/abstract; PMID:25805991; http://dx.doi.org/10.3389/fphar.2015.00021
- De Oliveira SN, Ryan C, Giannoni F, Hardee CL, Tremcinska I, Katebian B, Wherley J, Sahaghian A, Tu A, Grogan T, et al. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther [Internet] 2013; 24:824-39. Available from: http://online.liebertpub.com/doi/abs/10.1089/hum.2012.202; PMID:23978226; http://dx.doi.org/10.1089/hum.2012.202
- Larson S, De Oliveira SN. Gene-modified hematopoietic stem cells for cancer immunotherapy. Hum Vaccin Immunother [Internet] 2014 [cited 2014 May 26]; 10:982-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24398603; PMID:24398603; http://dx.doi.org/10.4161/hv.27637
- Kitchen SG, Bennett M, Galić Z, Kim J, Xu Q, Young A, Lieberman A, Joseph A, Goldstein H, Ng H, et al. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One [Internet] 2009 [cited 2013 May 23]; 4:e8208. Available from: http://dx.plos.org/10.1371/journal.pone.0008208; PMID:19997617; http://dx.doi.org/10.1371/journal.pone.0008208
- Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, Chan R, Bahner I, Gersuk V, Wang X, et al. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther [Internet] 2013 [cited 2013 May 22]; 21:1044-54. Available from: http://www.nature.com/doifinder/10.1038/mt.2013.8; PMID:23380815; http://dx.doi.org/10.1038/mt.2013.8
- Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, et al. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res [Internet] 2014 [cited 2015 Feb 19]; 74:5173-83. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-14-0376; PMID:25038231; http://dx.doi.org/10.1158/0008-5472.CAN-14-0376
- Gschweng E, De Oliveira S, Kohn DB. Hematopoietic stem cells for cancer immunotherapy. Immunol Rev [Internet] 2014 [cited 2013 Dec 18]; 257:237-49. Available from: http://doi.wiley.com/10.1111/imr.12128; PMID:24329801; http://dx.doi.org/10.1111/imr.12128
- Starck L, Popp K, Pircher H, Uckert W. Immunotherapy with TCR-redirected T cells: Comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T Cells. J Immunol [Internet] 2014; 192:206-13. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1202591; PMID:24293634; http://dx.doi.org/10.4049/jimmunol.1202591
- Najjar AM, Manuri PR, Olivares S, Flores L, Mi T, Huls H, Shpall EJ, Champlin RE, Turkman N, Paolillo V, et al. Imaging of sleeping beauty-modified CD19-specific T cells expressing HSV1-Thymidine Kinase by positron emission tomography. Mol Imaging Biol [Internet] 2016; Epub ahead of print. Available from: http://link.springer.com/10.1007/s11307-016-0971-8; PMID:27246312
- Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science [Internet] 1997 [cited 2013 Jul 9]; 276:1719-24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9180086; PMID:9180086; http://dx.doi.org/10.1126/science.276.5319.1719
- Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F, Bonini C, Bordignon C. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood [Internet] 2007 [cited 2013 Jul 9]; 109:4708-15. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2006-04-015230; PMID:17327417; http://dx.doi.org/10.1182/blood-2006-04-015230
- Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F, Bordignon C. The suicide gene therapy challenge: How to improve a successful gene therapy approach. Mol Ther [Internet] 2007; 15:1248-52. Available from: http://www.nature.com/doifinder/10.1038/sj.mt.6300190; PMID:17505474; http://dx.doi.org/10.1038/sj.mt.6300190
- Kokoris MS, Black ME. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci [Internet] 2009; 11:2267-72. Available from: http://doi.wiley.com/10.1110/ps.2460102; http://dx.doi.org/10.1110/ps.2460102
- Blumenthal M, Skelton D, Pepper KA, Jahn T, Methangkool E, Kohn DB. Effective suicide gene therapy for Leukemia in a model of insertional oncogenesis in mice. Mol Ther [Internet] 2007; 15:183-92. Available from: http://www.nature.com/doifinder/10.1038/sj.mt.6300015; PMID:17164790; http://dx.doi.org/10.1038/sj.mt.6300015
- Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D, Schiedlmeier B, Sebire NJ, Gaspar HB, Kinnon C, et al. Self-inactivating Gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther [Internet] 2008; 16:590-8. Available from: http://www.nature.com/doifinder/10.1038/sj.mt.6300393; PMID:18180772; http://dx.doi.org/10.1038/sj.mt.6300393
- Challita PM, Skelton D, El-Khoueiry A, Yu XJ, Weinberg K, Kohn DB. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol [Internet] 1995; 69:748-55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7815539; PMID:7815539
- Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature [Internet] 1992; 356:607-9. Available from: http://www.nature.com/doifinder/10.1038/356607a0; PMID:1313950; http://dx.doi.org/10.1038/356607a0
- Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat Biotechnol [Internet] 2002; 20:70-5. Available from: http://www.nature.com/doifinder/10.1038/nbt0102-70; PMID:11753365; http://dx.doi.org/10.1038/nbt0102-70
- Barese CN, Krouse AE, Metzger ME, King CA, Traversari C, Marini FC, Donahue RE, Dunbar CE. Thymidine kinase suicide gene-mediated ganciclovir ablation of autologous gene-modified rhesus hematopoiesis. Mol Ther [Internet] 2012; 20:1932-43. Available from: http://www.nature.com/doifinder/10.1038/mt.2012.166; PMID:22910293; http://dx.doi.org/10.1038/mt.2012.166
- Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther [Internet] 2010 [cited 2013 Jun 26]; 21:241-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20121594; PMID:20121594; http://dx.doi.org/10.1089/hum.2010.014
- Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJN. CD28 Costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res [Internet] 2006; 66:10995-1004. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-06-0160; PMID:17108138; http://dx.doi.org/10.1158/0008-5472.CAN-06-0160
- Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest [Internet] 2011 [cited 2013 Jun 25]; 121:1822-6. Available from: http://www.jci.org/articles/view/46110; PMID:21540550; http://dx.doi.org/10.1172/JCI46110
- Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim S, Grandi P, et al. CAR-Engineered NK cells targeting Wild-Type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep [Internet] 2015; 5:11483. Available from: http://www.nature.com/articles/srep11483; PMID:26155832; http://dx.doi.org/10.1038/srep11483
- Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred Tumor-specific T Cells. J Immunother [Internet] 2010; 33:1-7. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002371-201001000-00001; PMID:19952961; http://dx.doi.org/10.1097/CJI.0b013e3181b88ffc
- Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev [Internet] 2014; 257:56-71. Available from: http://doi.wiley.com/10.1111/imr.12132; PMID:24329789; http://dx.doi.org/10.1111/imr.12132
- Aiuti A. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (80) [Internet] 2002; 296:2410-3. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.1070104; http://dx.doi.org/10.1126/science.1070104
- Kohn DB, Pai S-Y, Sadelain M. Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. Biol Blood Marrow Transplant [Internet] 2013 [cited 2013 Jun 21]; 19:S64-9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1083879112003990; PMID:23032601; http://dx.doi.org/10.1016/j.bbmt.2012.09.021
- Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol [Internet] 1998; 72:8463-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9765382; PMID:9765382
- Cooper LJN. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood [Internet] 2003 [cited 2010 Jul 3]; 101:1637-44. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2002-07-1989; PMID:12393484; http://dx.doi.org/10.1182/blood-2002-07-1989
- Higashimoto T, Urbinati F, Perumbeti A, Jiang G, Zarzuela A, Chang LJ, Kohn DB, Malik P. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther [Internet] 2007; 14:1298-304. Available from: http://www.nature.com/doifinder/10.1038/sj.gt.3302979; PMID:17597793; http://dx.doi.org/10.1038/sj.gt.3302979
- Zanta-Boussif MA, Charrier S, Brice-Ouzet A, Martin S, Opolon P, Thrasher AJ, Hope TJ, Galy A. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther [Internet] 2009; 16:605-19. Available from: http://www.nature.com/doifinder/10.1038/gt.2009.3; PMID:19262615; http://dx.doi.org/10.1038/gt.2009.3
- Cooper AR, Patel S, Senadheera S, Plath K, Kohn DB, Hollis RP. Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J Virol Methods [Internet] 2011; 177:1-9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166093411002837; PMID:21784103; http://dx.doi.org/10.1016/j.jviromet.2011.06.019
- Zu B, Shi Y, Xu M, You G, Huang Z, Gao M, Feng W. ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells. J Exp Clin Cancer Res [Internet] 2015; 34:56. Available from: http://jeccr.biomedcentral.com/articles/10.1186/s13046-015-0139-4; PMID:26017281; http://dx.doi.org/10.1186/s13046-015-0139-4
- Dong XY, Wang WQ, Zhao Y, Li XD, Fang ZG, Lin DJ, Xiao RZ, Huang R-W, Pan GJ, Liu JJ. Antibody-directed double suicide gene therapy targeting of MUC1- positive leukemia cells in vitro and in vivo. Curr Gene Ther [Internet] 2013; 13:346-57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24060312; PMID:24060312; http://dx.doi.org/10.2174/15665232113136660029